Intelligent Bio Solutions Inc Share Price (INBS.US)

INBS is a strange little company that few people will be aware of it. Its technology originated in Norwich/Cambridge (UK), it is managed out of Australia, and it is listed in the US. INBS has a rapid point-of-care test to detect alcohol and drugs based on a simple fingerprint (sweat) sample. IMHO every transport company (delivery drivers, truck drivers, taxi providers, pilots etc) , and for that matter, surgeons , should be using this simple test every day to make sure that their drivers and pilots are not under the influence. It is CE marked, but most of current sales are derived from the UK. Performance in 2025 has been really poor because, as with all developing companies, INBS needed working capital injections. But the real hit came when the FDA decided that it needed more data in order to be able to approve its 510(k) submission, so approval was delayed to 2026 (hopefully). With 450 accounts across 24 countries, cartridge sales are now rising sharply and new readers are sold as more accounts are added. But the real opportunity is in the US, so FDA approval is key.

To show the potential, yesterday the company announced a partnership with a specialist global medical device producer (Syrma Johari MedTech) to increase capacity four-fold and at a much reduced manufacturing cost. While good news, I was surprised that the share price rose 200% by mid-afternoon and came off a little when it announced a $10m Private Placement, but still ended day up 135%. Just imagine what would happen with FDA approval. Admittedly, this is a high-risk punt, but rewards could be substantial in 2026.

https://investors.ibs.inc/news/news-details/2025/Intelligent-Bio-Solutions-Announces-New-Manufacturing-Partnership-to-Strengthen-Global-Production-Capability-and-Increase-Margins/default.aspx

For transparency, I loved the technology, but got in far too early. Yesterdays move gets me back to within $0.5 of breakeven.